Constantine S. Mitsiades

33.9k total citations · 7 hit papers
296 papers, 20.0k citations indexed

About

Constantine S. Mitsiades is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Constantine S. Mitsiades has authored 296 papers receiving a total of 20.0k indexed citations (citations by other indexed papers that have themselves been cited), including 213 papers in Molecular Biology, 203 papers in Hematology and 107 papers in Oncology. Recurrent topics in Constantine S. Mitsiades's work include Multiple Myeloma Research and Treatments (191 papers), Protein Degradation and Inhibitors (81 papers) and Ubiquitin and proteasome pathways (61 papers). Constantine S. Mitsiades is often cited by papers focused on Multiple Myeloma Research and Treatments (191 papers), Protein Degradation and Inhibitors (81 papers) and Ubiquitin and proteasome pathways (61 papers). Constantine S. Mitsiades collaborates with scholars based in United States, Greece and Netherlands. Constantine S. Mitsiades's co-authors include Kenneth C. Anderson, Paul G. Richardson, Teru Hideshima, Nicholas Mitsiades, Dharminder Chauhan, Nikhil C. Munshi, Vassiliki Poulaki, Robert Schlossman, Klaus Podar and Steven P. Treon and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Constantine S. Mitsiades

291 papers receiving 19.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

2013 1.1k citations Gang Lu, Richard E. Middleton et al. Science profile →
NF-κB as a Therapeutic Target in Multiple Myeloma

2002 752 citations Teru Hideshima, Dharminder Chauhan et al. profile →
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

2007 702 citations Teru Hideshima, Constantine S. Mitsiades et al. profile →
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

2002 630 citations Paul G. Richardson, Robert Schlossman et al. Blood profile →
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

2003 575 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

2005 560 citations Dharminder Chauhan, Klaus Podar et al. profile →
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

2002 544 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Constantine S. Mitsiades United States	68	14.1k	9.5k	7.3k	2.4k	2.2k	296	20.0k
Robert Z. Orlowski United States	66	13.2k 0.9×	9.7k 1.0×	8.3k 1.1×	1.5k 0.6×	1.4k 0.6×	514	18.6k
Noopur Raje United States	74	12.0k 0.8×	11.2k 1.2×	10.1k 1.4×	2.8k 1.2×	1.3k 0.6×	497	20.3k
Sagar Lonial United States	70	12.3k 0.9×	11.9k 1.3×	8.8k 1.2×	2.0k 0.9×	1.4k 0.6×	691	18.9k
Dharminder Chauhan United States	92	19.9k 1.4×	14.9k 1.6×	11.1k 1.5×	3.8k 1.6×	2.5k 1.1×	355	28.2k
Nicholas Mitsiades United States	66	10.1k 0.7×	4.6k 0.5×	4.5k 0.6×	1.9k 0.8×	2.4k 1.1×	172	15.3k
Klaus Podar United States	63	8.7k 0.6×	6.6k 0.7×	4.6k 0.6×	1.8k 0.8×	1.3k 0.6×	186	12.8k
Steven Grant United States	79	16.7k 1.2×	3.6k 0.4×	6.3k 0.9×	2.2k 0.9×	2.3k 1.1×	451	23.2k
Anthony Letai United States	62	12.2k 0.9×	3.7k 0.4×	4.5k 0.6×	2.9k 1.2×	2.1k 0.9×	175	18.2k
Craig T. Jordan United States	62	10.2k 0.7×	6.6k 0.7×	4.5k 0.6×	3.0k 1.3×	3.6k 1.6×	237	17.3k
Marina Konopleva United States	94	15.8k 1.1×	15.6k 1.6×	7.9k 1.1×	4.0k 1.7×	3.4k 1.6×	917	30.5k

Countries citing papers authored by Constantine S. Mitsiades

Since Specialization

Citations

This map shows the geographic impact of Constantine S. Mitsiades's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constantine S. Mitsiades with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constantine S. Mitsiades more than expected).

Fields of papers citing papers by Constantine S. Mitsiades

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constantine S. Mitsiades. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constantine S. Mitsiades. The network helps show where Constantine S. Mitsiades may publish in the future.

Co-authorship network of co-authors of Constantine S. Mitsiades

This figure shows the co-authorship network connecting the top 25 collaborators of Constantine S. Mitsiades. A scholar is included among the top collaborators of Constantine S. Mitsiades based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constantine S. Mitsiades. Constantine S. Mitsiades is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riva, Alberto, Benjamin G. Barwick, Sayantan Maji, et al.. (2024). KDM6A regulates immune response genes in multiple myeloma. Blood. 144(14). 1508–1520. 5 indexed citations

Yao, Yao, Mehmet Samur, Eugenio Morelli, et al.. (2023). CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 141(23). 2841–2852. 17 indexed citations

Sanderson, Michael P., Manja Friese‐Hamim, Michael Busch, et al.. (2021). M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models. Molecular Cancer Therapeutics. 20(8). 1378–1387. 30 indexed citations

Duy, Cihangir, Meng Li, Matt Teater, et al.. (2021). Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discovery. 11(6). 1542–1561. 153 indexed citations

Dhimolea, Eugen, Ricardo De Matos Simoes, Xiang Weng, et al.. (2020). Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. Cancer Research. 81(2). 371–383. 12 indexed citations

Schwede, Matthew, Levi Waldron, Samuel C. Mok, et al.. (2019). The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention. 29(2). 509–519. 24 indexed citations

Tang, Min, Rui Zhao, Helgi van de Velde, et al.. (2016). Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clinical Cancer Research. 22(16). 4206–4214. 20 indexed citations

Weisberg, Ellen, Atsushi Nonami, Chen Zhao, et al.. (2014). Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. Clinical Cancer Research. 20(21). 5483–5495. 14 indexed citations

Lu, Gang, Richard E. Middleton, Huahang Sun, et al.. (2013). The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science. 343(6168). 305–309. 1108 indexed citations breakdown →

10.

Donk, Niels W.C.J. van de, Monique C. Minnema, Julie H. Huang, et al.. (2013). Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance. Clinical Cancer Research. 19(20). 5591–5601. 51 indexed citations

11.

McMillin, Douglas W., Hannah M. Jacobs, Jake Delmore, et al.. (2012). Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. Molecular Cancer Therapeutics. 11(4). 942–951. 46 indexed citations

12.

Rickles, Richard J., Winnie F. Tam, Thomas P. Giordano, et al.. (2012). Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening. Molecular Cancer Therapeutics. 11(7). 1432–1442. 13 indexed citations

13.

Gaballa, Mahmoud, Jacob P. Laubach, Robert Schlossman, et al.. (2012). Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology. 5(1). 51–68. 24 indexed citations

14.

Jakubı́ková, Jana, Sophia Adamia, Maria Kost‐Alimova, et al.. (2011). Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 117(17). 4409–4419. 122 indexed citations

15.

Ooi, Melissa, Patrick Hayden, Vassiliki Kotoula, et al.. (2009). Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research. 15(23). 7153–7160. 53 indexed citations

16.

McMillin, Douglas W., Melissa Ooi, Jake Delmore, et al.. (2009). Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Cancer Research. 69(14). 5835–5842. 105 indexed citations

17.

Mitsiades, Constantine S., Cécile Rouleau, Cinara Echart, et al.. (2009). Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias. Clinical Cancer Research. 15(4). 1210–1221. 46 indexed citations

18.

Weisberg, Ellen, Renee D. Wright, Douglas W. McMillin, et al.. (2008). Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Molecular Cancer Therapeutics. 7(5). 1121–1129. 60 indexed citations

19.

Weisberg, Ellen, Andrew L. Kung, Renee D. Wright, et al.. (2007). Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics. 6(7). 1951–1961. 66 indexed citations

20.

Tai, YT, Klaus Podar, Reshma Shringarpure, et al.. (2003). Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta.. Blood. 102(11). 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact